Skip to main content

External Automatic Glaucoma Laser (EAGLE) for the first-line glaucoma treatment: Commercial prototype development and validation

Objective

The GLAUrious project is promoting the novel External Automatic Glaucoma Laser (EAGLE) device with the goal of providing accessible first-line treatment for glaucoma.
Glaucoma, a chronic disease causing progressive optic nerve degeneration, is the leading cause of irreversible blindness globally. Although incurable, disease progression is delayed by reducing intraocular pressure, thus preventing blindness. Some 64 million people worldwide suffer from glaucoma. Current first-line treatment requires daily eye drops, a strict regimen causing 50% patient dropout after 1 year.
Laser treatment for glaucoma has been in use for many years. Its effect lasts for 2−5 years and is repeatable. This traditional 10-minute procedure, involving contact with the patient’s eye, requires the expertise of glaucoma specialists. Consequently, costs are high and accessibility to the general population is low.
The novel EAGLE procedure is automated, non-invasive, non-contact, painless and user friendly—1 second of treatment by one press of a button. This revolutionary cost-effective device could be safely used by the world’s 212,000 ophthalmologists, thus becoming a primary treatment for glaucoma, overcoming serious problems of eye drop non-compliance and effectively preventing disease deterioration.
GLAUrious project aims to ease commercialization of the EAGLE device by securing clinical prototype validation, streamlining commercial production, optimizing component costs, disseminating to key opinion leaders and distributors, and refining commercial strategy. Validation of EAGLE will allow its commercialization enabling penetration of the ophthalmic market and boosting of the industrial consortium partners (BEL and MCI).
The multidisciplinary GLAUrious Consortium, with its four partners from three member states (Belgium, Italy, UK) and one associated state (Israel), incorporates two SMEs and two academic hospitals.

Coordinator

THE QUEEN'S UNIVERSITY OF BELFAST
Net EU contribution
€ 261 791,00
Address
University Road Lanyon Building
BT7 1NN Belfast
United Kingdom

See on map

Region
Northern Ireland Northern Ireland Belfast
Activity type
Higher or Secondary Education Establishments
Non-EU contribution
€ 0,00

Participants (4)

BELKIN VISION LTD
Israel
Net EU contribution
€ 1 575 658,00
Address
13 Gan Rave Boulevard 3rd Floor
8122214 Yavne

See on map

SME

The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.

Yes
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Non-EU contribution
€ 1 393 800,75
MAZO VSEVOLOD

Participation ended

Germany
Net EU contribution
€ 190 894,00
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Non-EU contribution
€ 81 812,00
MEDICAL CONSULTING AND INVESTMENT
Belgium
Net EU contribution
€ 187 250,00
Address
Willem Elsschotlaan 25
9150 Melsele

See on map

SME

The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.

Yes
Region
Vlaams Gewest Prov. Oost-Vlaanderen Arr. Sint-Niklaas
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Non-EU contribution
€ 80 250,50
UNIVERSITA DEGLI STUDI DI GENOVA
Italy
Net EU contribution
€ 264 682,00
Address
Via Balbi 5
16126 Genova

See on map

Region
Nord-Ovest Liguria Genova
Activity type
Higher or Secondary Education Establishments
Non-EU contribution
€ 0,00